From: Long-term effectiveness and safety of self-management of oral anticoagulants in real-world settings
Patients (N = 808) | |
---|---|
Gender, n (%) | |
Male | 499 (61.8) |
Female | 309 (38.2) |
Age groups, n (%) | |
< 50 | 168 (20.8) |
50–60 | 197 (24.4) |
60–75 | 311 (38.5) |
> 75 | 132 (16.3) |
Origin of the patient, n (%) | |
Primary healthcare | 340 (42.1) |
Specialized healthcare | 468 (57.9) |
Anticoagulant agent, n (%) | |
Acenocoumarol | 791 (97.9) |
Warfarin | 17 (2.1) |
Target INR, n (%) | |
2.0–3.0 | 610 (75.5) |
2.5–3.5 | 182 (22.5) |
Other | 16 (2.0) |
Indication for anticoagulation, n (%) | |
Mechanical heart valve | 204 (25.2) |
Atrial fibrillation/ Atrial flutter | 344 (42.6) |
Venous and arterial thrombosis | 111 (13.7) |
Others | 148 (18.3) |
Unknown | 1 (0.1) |
Time of follow-up, median years (IQR) | 3.3 (0.0–5.0) |
Required a responsible caregiver to PSM a | 107 (14.0) |
Study withdrawal, n (%) | 177 (21.9) |
Death | 59 (7.3) |
End of treatment | 42 (5.2) |
Never performed PSM | 36 (4.5) |
Voluntary withdrawal | 28 (3.5) |
Loss to follow-up | 8 (1.0) |
Others | 4 (0.5) |